Author Archives: Malika Ammam, PhD

Potential Therapeutic Target for Drug-resistant Multiple Myelomas Identified in Study

A subunit of a signaling protein may be a new therapeutic target in multiple myeloma (MM), a hematologic malignancy with high relapse rates and resulting drug resistance in patients, according to  researchers at the Tokyo Women’s Medical University. The study, “Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma,” published in …

Takeda Publishes Promising Trial Results on Ixazomib, an Approved Drug to Treat Relapsed Multiple Myeloma

Takeda Pharmaceutical has published promising data from the TOURMALINE-MM1 Phase 3 clinical trial of patients with relapsed and/or refractory multiple myeloma (MM), treated with the combination of once-weekly oral Ninlaro (ixazomib) capsules and lenalidomide-dexamethasone or placebo and lenalidomide-dexamethasone. The results, also presented at the 57th Annual Meeting of the American Society of Hematology (ASH)…